The global peripheral vascular devices market is undergoing a significant transformation as rising cases of cardiovascular and lifestyle-related disorders push healthcare systems toward advanced, minimally invasive treatment solutions. Peripheral vascular devices are specialized medical tools used to open or restore blood flow in vessels located outside the heart, particularly in the arms and legs. These devices play a critical role in treating conditions where blood vessels become narrowed or blocked, often leading to symptoms such as pain while walking, delayed wound healing, and in severe cases, the risk of limb amputation. As the global burden of vascular disease continues to climb, the demand for these devices is accelerating across hospitals, specialty clinics, and diagnostic centers worldwide.

Market Size and Growth Trajectory

According to Fortune Business Insight, the global peripheral vascular devices market was valued at USD 12.04 billion in 2025 and is projected to grow from USD 12.62 billion in 2026 to USD 19.42 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period. This steady upward trend highlights the growing reliance on peripheral vascular interventions as frontline solutions for managing circulatory disorders, especially as populations age and the prevalence of diabetes and related vascular complications continues to rise.

Key Drivers Fueling Market Expansion

One of the most significant forces propelling this market forward is the increasing burden of peripheral artery disease (PAD) worldwide. According to Fortune Business Insight, an estimated 236 million adults globally were living with peripheral artery disease as of June 2021, underscoring the scale of unmet medical need. As hospitals encounter a growing number of PAD cases, they are increasingly adopting newer, more effective tools designed to improve patient outcomes and reduce the likelihood of repeat procedures. This rising clinical demand is, in turn, encouraging manufacturers to pursue new product approvals and expand their device portfolios.

Lifestyle-related conditions, including obesity, sedentary habits, and poor dietary patterns, are also contributing to a rise in blood-circulation issues, further amplifying the need for peripheral vascular interventions. Hospitals are additionally showing a strong preference for treatments that shorten recovery times, which has made minimally invasive procedures increasingly common in clinical practice. Alongside this, continuous technological advancements in device design and materials are helping to improve procedural accuracy and patient safety, reinforcing the market’s growth momentum.

Industry activity reflects this innovation-driven push. According to Fortune Business Insight, Abbott received FDA approval in April 2024 for its Esprit BTK Everolimus eluting resorbable scaffold system, a device specifically engineered to regulate blood flow in the lower leg. Similarly, in January 2024, Reflow Medical secured CE approval for its Spur peripheral retrievable stent system, designed to treat complex peripheral arterial disease, including hard-to-reach below-the-knee vessels. Such developments illustrate how manufacturers are increasingly focusing on smaller, more intricate vascular regions that were previously difficult to treat effectively.

A notable trend shaping the industry is the expanding range of clinical applications for peripheral vascular devices. Hospitals are reporting a rise in patients presenting with severe leg circulation problems, particularly those linked to diabetes. This shift is prompting device makers to design solutions tailored for smaller and more complex vessels. As more below-the-knee (BTK) focused products gain regulatory approval, clinicians are gaining greater confidence to intervene earlier and manage complicated cases with improved precision.

Market Restraints and Challenges

Despite strong growth prospects, the market faces notable headwinds. Peripheral vascular devices are subject to intense regulatory scrutiny given their use in critical blood vessels, and healthcare providers demand clear clinical evidence of safety and efficacy before adopting new products. This cautious approach can slow adoption rates, increase the burden of clinical studies, and delay product launches across different regions.

Pricing pressure represents another critical challenge, particularly within hospital procurement systems that rely on tenders and group purchasing arrangements. When institutions evaluate multiple comparable devices, cost often becomes the deciding factor, which can compress manufacturer margins and extend negotiation timelines. To remain competitive, companies are increasingly turning to bundled pricing, discounts, and extended service agreements.

Segmental Insights

By product, the market is categorized into vascular access and entry devices, vascular navigation and delivery devices, intravascular diagnostic and imaging devices, thrombus and embolus management devices, peripheral stents, and others. According to Fortune Business Insight, the peripheral stent segment is anticipated to hold the largest market share, owing to its superior treatment outcomes and broad applicability across varying levels of patient severity. Meanwhile, the thrombus and embolus management devices segment is expected to post the fastest growth, with a projected CAGR of 6.6% through the forecast period.

In terms of application, the market spans peripheral arterial disorders, aneurysmal disease, venous diseases, and others, with peripheral arterial disorders dominating in 2025 due to the widespread global prevalence of PAD. By end-user, hospitals accounted for the largest share and are expected to hold approximately 61.8% of the market in 2026, according to Fortune Business Insight, owing to their advanced imaging capabilities, specialist care teams, and capacity for post-procedure monitoring.

Regional Outlook

North America led the global market, commanding a 40.78% share in 2025 and reaching a valuation of USD 4.91 billion, according to Fortune Business Insight. The region’s dominance is attributed to strong adoption of minimally invasive procedures and advancements in bio-absorbable stent technology. Europe followed as the second-largest market, projected to reach USD 3.41 billion in 2026 with a 5.0% growth rate, while Asia Pacific is estimated to secure the third-largest position, valued at USD 2.87 billion in 2026.

Competitive Landscape

The market features a semi-consolidated structure dominated by major players, including Abbott, Medtronic, Boston Scientific Corporation, Terumo Corporation, and BD. According to Fortune Business Insight, these companies maintain their market positions through continuous investment in innovation and strategic product approvals. In July 2025, Teleflex Incorporated completed the acquisition of Biotronik’s vascular intervention business, marking one of the sector’s notable consolidation moves. Other prominent players, such as Cook Medical, Cardinal Health, Merit Medical Systems, and Getinge, are expected to pursue collaborative strategies to strengthen their market presence going forward.

Conclusion

The peripheral vascular devices market stands at an important juncture, driven by rising disease prevalence, technological innovation, and a global shift toward minimally invasive care. While regulatory scrutiny and pricing pressures present ongoing challenges, the market’s long-term outlook remains strong, supported by expanding clinical applications and sustained investment from key industry players.

What’s Driving Japan’s Market? Discover the Latest “Peripheral Vascular Devices” Insights

https://www.fortunebusinessinsights.com/jp/%E6%9C%AB%E6%A2%A2%E8%A1%80%E7%AE%A1%E3%83%87%E3%83%90%E3%82%A4%E3%82%B9%E5%B8%82%E5%A0%B4-115399